Overnutrition and sedentary lifestyle have increased the global prevalence of diabetes and obesity [1]. In addition, the accompanying metabolic derangements, cardiovascular diseases [2], non-alcoholic fatty liver disease [3], and different malignant diseases also heavily impact public health and economic burden worldwide. Insulin resistance, the essence of metabolic syndrome with a constellation of metabolic derangements as well as risk factors for both cardiovascular diseases and diabetes [2], is known to aggravate hepatic steatosis, drive liver fibrosis progression, and increase the risk of hepatocellular carcinoma (HCC) [4]. Therefore, metabolic factors and their adjustments have been increasingly recognized in the clinical practice of hepatology, and become hot subjects in this active research field [5]. In the meantime, hepatitis C virus (HCV) infection affects [170 million people with severe liver disease, including chronic hepatitis, liver fibrosis, cirrhosis, and HCC [6]. Therefore, HCV infection bears a huge disease burden globally, and it is prudent to eradicate the virus and halt disease progression in patients with chronic HCV infection. Unfortunately, the current standard of care with pegylated interferon-a plus ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) is costly, poorly tolerated, and only effective in a certain portion of patients [7]. With these reasons, identifying and modifying factors associated with disease progression or predictive of therapeutic response in CHC patients is a matter of clinical concern. Of note, ample epidemiologic and clinical evidence has demonstrated a close association of HCV infection with metabolic derangements [8]. CHC patients are known to have an increased prevalence of diabetes and hepatic steatosis. In addition, serum lipid profiles of CHC patients are different from healthy or other disease control subjects. For example, CHC patients usually have lower serum triglyceride, total cholesterol, but higher serum adiponectin, homeostasis model assessment (HOMA)-insulin resistance index, and serum high-density lipoprotein (HDL) levels than matched healthy adults [9]. Moreover, serum HCV RNA levels were positively proportional to HOMA-insulin resistance index, serum triglyceride, and total cholesterol levels in CHC patients [10, 11]. Additionally, several lines C.-S. Hsu Division of Gastroenterology, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei, Taiwan